Chemotherapy-induced Raynaud's phenomenon

Toumbis-Ioannou, Eugenia; Cohen, Philip R.

doi:10.3949/ccjm.61.3.195

Cited by 14 publications

(9 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…13 The proposed mechanism of action for the vasospastic adverse effect is the promotion of distal artery and arteriole constriction. 3 Treatment should include protection against cold exposure. Warm socks should be worn at all times, and other protective clothing should be worn when outside.…”

Section: Discussionmentioning

confidence: 99%

“…2 As in the patient described above, symptoms should improve (they rarely worsen) with cessation of the offending medication. 3 Vincristine is metabolized by the cytochrome P450 iso zymes 3A4 (CYP3A4) and 3A5 (CYP3A5), and variants can affect the pharmacokinetics of vincristine. Ongoing research is evaluating the use of pharmacogenomics to pre dict adverse drug reactions to antineoplastic agents such as vincristine, and several studies have identified genes that may increase the risk of adverse reactions, although no data are specifically for vincristineinduced vasospastic changes such as those in the patient described above.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Vincristine-Induced Acrocyanosis and Erythema Pernio

Middleton

Boswell

Houwink

et al. 2023

J Prim Care Community Health

View full text Add to dashboard Cite

Introduction: Acrocyanosis and erythema pernio are 2 dermatologic manifestations of vasospastic changes. Primary care providers should consider that these conditions can occur as primary or idiopathic conditions and as secondary conditions related to another disease or medication. Herein we describe a case of acrocyanosis and erythema pernio attributed to vincristine therapy. Case Description: A 22-year-old man was evaluated for discomfort and red lesions involving the toes of both feet for several weeks. He had completed chemotherapy 1 month earlier for Ewing sarcoma in the right femur. Local control for the primary tumor included wide local excision and reconstruction with a vascularized fibular allograft from the right fibula. On examination, his right foot was dark blue and cool. Toes on both feet had nonpainful erythematous papules. After the case was discussed with the patient’s oncology team, the diagnosis was medication-induced acrocyanosis of the right foot and bilateral erythema pernio. Treatment consisted of supportive care to keep the feet warm and promote circulation to the feet. At 2-week follow-up, the patient’s symptoms and the appearance of his feet had markedly improved. Discussion: Primary care clinicians should be able to recognize dermatologic manifestations of vasospastic changes, including acrocyanosis and erythema pernio, and rule out possible secondary causes, such as pharmacologic agents. This patient’s history of therapy for Ewing sarcoma prompted consideration of medication-induced vasospastic changes most likely related to the adverse vasospastic effects of vincristine. Symptoms should improve with cessation of the offending medication.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Vincristine-Induced Acrocyanosis and Erythema Pernio

Middleton

Boswell

Houwink

et al. 2023

J Prim Care Community Health

View full text Add to dashboard Cite

show abstract

“…Выделяют 2 варианта течения заболевания: первичная болезнь Рейно и вторичный феномен Рейно. На фоне приема химиотерапевтических препаратов (блеомицин, цисплатин), гормональных препаратов (эстрадиол) возникает вторичный феномен Рейно [24], что является наиболее распространенным сосудистым осложнением после ХТ [25].…”

Section: феномен рейноunclassified

“…Также следует отметить, что феномен Рейно выделяют в составе паранеопластического синдрома. В ряде исследований появление симптомов феномена Рейно свидетельствует об активности онкологического процесса [25,26]. Однако у части пациентов с первичным паранеопластическим процессом развивается склеродермоподобный синдром уже после диагностики онкологического процесса, что, в свою очередь, свидетельствует о роли специфической терапии онкологических заболеваний в возникновении системной склеродермии.…”

Section: феномен рейноunclassified

Late complications of the treatment of patients with germ cell tumors

et al. 2020

View full text Add to dashboard Cite

Germ cell tumors are one of the highly sensitive to chemotherapy, and about 80 % of patients can be cured even having metastases. Apartfrom acute toxicity, chemotherapy is characterized by late complications that occur many years later and not only negatively affect the quality of life, but in some cases are life-threatening. The review summarizes the results of studies on the late complications’ occurrence and prevention when treating patients with germ cell tumors.

show abstract

“…It seldom results in considerable functional impairment and usually resolves on its own, especially after the inciting antineoplastic medication is stopped. Nevertheless, it frequently returns after the reintroduction of the agent causing it [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Paclitaxel-Induced Cutaneous Lupus Erythematosus and Raynaud's Phenomenon

Rusia,

Madke,

Kashikar

et al. 2023

Cureus

View full text Add to dashboard Cite

Taxanes, in combination with platinum-based drugs, are considered the initial treatment option for certain types of cancer, including ovarian cancer. Here, we report the case of a 59-year-old woman who developed a malar rash on her face, a maculopapular rash on her forearms, and bluish discoloration on her fingers immediately following the end of the third cycle of chemotherapy. After discontinuing paclitaxel and using oral and topical steroids for rash and diltiazem and topical minoxidil for the treatment of Raynaud's phenomenon, the symptoms completely resolved. While taxanes are known to cause drug-induced lupus, there has never been any information on taxanes causing isolated Raynaud's phenomenon. This is the first case report that suggests paclitaxel-induced Raynaud's phenomenon along with paclitaxel-induced lupus.

show abstract

Chemotherapy-induced Raynaud's phenomenon

Cited by 14 publications

References 15 publications

Vincristine-Induced Acrocyanosis and Erythema Pernio

Vincristine-Induced Acrocyanosis and Erythema Pernio

Late complications of the treatment of patients with germ cell tumors

Paclitaxel-Induced Cutaneous Lupus Erythematosus and Raynaud's Phenomenon

Contact Info

Product

Resources

About